Rare diseases
Investigational molecules
Locations
Keskussairaalankatu 7, 15850 Lahti, Finland
Paeijaet-Haemeen hyvinvointialue in Lahti, Finland specialises in clinical trials of conditions such as Colitis ulcerative, Colorectal cancer, Colorectal cancer metastatic, Crohn's disease, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in rheumatology, with a particular focus on autoimmune diseases such as Giant Cell Arteritis (GCA). The institution is dedicated to advancing the understanding and treatment of these complex conditions.
Through cutting-edge research, the center is exploring novel therapeutic strategies, including the use of biologics like secukinumab, to improve patient outcomes and quality of life.
Specializing in oncology, the medical center is renowned for its research in breast cancer, particularly in high-risk, node-positive, early-stage cases. The focus is on developing and evaluating new treatment regimens to enhance patient care.
The center is actively involved in clinical trials assessing the efficacy of novel agents like abemaciclib, aiming to provide more effective and personalized treatment options for patients.
Clinical trials currently enrolling participants at this site.
Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
FinlandEvaluating the effect of recombinant varicella zoster virus glycoprotein E on the risk of dementia in adults aged 76 years and older
FinlandStudy Comparing Intravenous Contrast CT with Non-Contrast CT for Patients with Acute Abdominal Pain and Reduced Kidney Function Using Iohexol
FinlandStudy on the Effects of Fluorouracil and Capecitabine in Patients with Metastatic Colorectal Cancer
FinlandStudy on Fecal Microbiota Transplantation with Infliximab and Vedolizumab for Patients with Ulcerative Colitis
FinlandStudy of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety
FinlandGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
